South Korea Diabetes Drugs Market

South Korea Diabetes Drugs Market Size Report – In a Glance

As per the survey report on South Korea diabetes drugs market, the market is expected to foresee a CAGR value of 3.43% during 2025-2035, and further generate a market size of USD 1.53 billion by the end of 2035. In 2024, the market size was value at USD 1.05 billion revenue.

• The South Korea diabetes drugs market’s growth is driven by rising prevalence of diabetes.
• KDMI analyst’s growth analysis foresees expensive innovative treatments as the restraint for South Korea diabetes drugs market.

South Korea Diabetes Drugs Market Analysis

Diabetes drug are medications used to manage blood sugar levels in people with diabetes. These drugs are categorized into insulin and non-insulin medications, with each category possessing specific properties. Insulin is a specific hormone that help body to utilize glucose for energy, while non-insulin drugs are used to simulate insulin release and reduce absorption or production of glucose. The South Korea diabetes drugs market growth is driven by rising prevalence of diabetes and increasing demand for advanced technological tools and equipment to provide treatments and therapies. According to the statistics report by International Diabetes Federation, the prevalence of diabetes in South Korea accounts for 9.6 per cent and total cases of diabetes as of 2024 were more than 50 lakhs, which drives the demand for effective medications, leading to the market growth. AstraZeneca, Eli Lily, and Sanofi Aventis are some of the significant participants in the South Korea diabetes drugs market.

South Korea Diabetes Drugs Market Growth Drivers and Restraints

Growth Drivers

• Rising prevalence of Diabetes and aging population – South Korea’s elderly population is significantly growing which drives the market growth of diabetes drugs market. The study report shows, 18% of region’s population is aged 60 and above, which may grow and surpass Japan’s aging population by 2045. Also, by 2072, more than half of Korea’s population will be aged 65 and over, which demands for effective medications in healthcare sector. Diabetes is a age-related disease that highly impacts elder people and they require timely, frequent medical check-ups to track their health reports and get timely treatments. The growing number of diabetic patients, emphasizes medical industry to implement advanced solutions in treatment procedures to overcome deficiencies of traditional techniques. With the adoption of innovative tools, the market will boost by sustaining long-term effectiveness of treatment procedures.
• Government support, digitalization, and development of healthcare infrastructure – South Korean diabetes drugs market growth is also propelled by government supporting adoption and integration of advanced, innovative technologies in medical sector. The digitalization plays major role in supporting healthcare industry by overcoming certain inefficiencies of traditional procedures and reduces recovery time by developing minimally or non-invasive treatment techniques. The supportive policies by government emphasizes organizations to increasingly invest in research and development of healthcare infrastructure to make it accessible and affordable for middle-class patients. These factors contribute to the South Korea diabetes drugs market growth.

Restraints

• Expensive innovative treatments – The advancement is necessary in healthcare treatment procedures, but the costs associated with research and development, implementation, utilization, and maintenance costs are very high, which leads to increase in treatment costs, making it expensive for middle-income individuals. Due to price restrictions, many people refrain from accessing advanced, innovative treatment procedures and their benefits, and prefer traditional methods. Also, limited or no reimbursement impacts the accessibility of innovative treatments, that limits the market growth.

South Korea Diabetes Drugs Market Segmentation

Our experts at KD Market Insights have segmented the South Korea diabetes drugs market research report as:

Analyst’s Observation on South Korea Diabetes Drugs Market Recent Developments

Over the years, the experts at KD Market Insights have been observing the recent developments associated with South Korea diabetes drugs market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

Daewoong Pharmaceuticals has announced its approval obtainment for SGLT-2 inhibitor+metformin drug in just one month after the release of Envlo Tab, the 1st SGLT-2 inhibitor by Korea. Envlo Tab has been approved for dietary and exercise therapies to improve blood glucose control, while metformin is used for the first time for type 2 diabetes.

Merck Biopharma Korea has entered into partnership with LG Chem to distribute Glucophage family of type 2 diabetes treatment in Korea. The Glucophage family includes Glucophage IR, Glucophage XR, and Glucovance. The partnership is a move to combine Merck’s expertise in quality management with LG Chem’s marketing and sales network to enhance market presence in Korea’s market.

South Korea Diabetes Drugs Market Competitive Landscape

Some of the significant participants who top the South Korea diabetes drugs market share:

• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly and Company
• Sanofi Aventis
• Novo Nordisk A/S